BridgeBio Pharma Financials - Benzinga

BridgeBio Pharma Inc

BBIONASDAQ

Trade with Public

Trade with Public

$66.61

1.041.59%

近くで: Sep 28, 5:00 PM EST

$66.60

-0.01-0.02%

時間外: 4:48 PM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

BridgeBio Pharma Financials

BridgeBio Pharma (BBIO) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
BridgeBio Pharma Q2 EPS $(0.78) Misses $(0.59) Estimate, Sales $243.676M Beat $218.743M Estimate

BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.59) by 32.2 percent. This is a 17.89 percent increase over losses of $(0.95) per share

Benzinga Newsdesk

PRO
BridgeBio Pharma Q1 EPS $(0.84) Misses $(0.67) Estimate, Sales $194.515M Beat $177.937M Estimate

BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.67) by 25.37 percent. This is a 4.55 percent increase over losses of $(0.88) per share from

Benzinga Newsdesk

BridgeBio Pharma Earnings Review: Q4 Summary

Benzinga Insights

PRO
BridgeBio Pharma Q4 EPS $(1.00) Misses $(0.66) Estimate, Sales $154.178M Beat $146.844M Estimate

BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $(0.66) by 52.67 percent. This is a 28.57 percent increase over losses of $(1.40) per share

Benzinga Newsdesk

Earnings Scheduled For February 24, 2026

Benzinga Insights

Insights Ahead: BridgeBio Pharma's Quarterly Earnings

Benzinga Insights

© 2026 Benzinga | All Rights Reserved